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Abstract
Purpose Hypoxia has been shown to reduce energy
intake and lead to weight loss, but the underlying mecha-
nisms are unclear. The aim was therefore to assess changes
in eating after rapid ascent to 4,559 m and to investigate to
what extent hypoxia, acute mountain sickness (AMS), food
preferences and satiation hormones influence eating
behavior.
Methods Participants (n = 23) were studied at near sea
level (Zurich (ZH), 446 m) and on two days after rapid
ascent to Capanna Margherita (MG) at 4,559 m (MG2 and
MG4). Changes in appetite, food preferences and energy
intake in an ad libitum meal were assessed. Plasma con-
centrations of cholecystokinin, peptide tyrosine–tyrosine,
gastrin, glucagon and amylin were measured. Peripheral
oxygen saturation (SpO2) was monitored, and AMS
assessed using the Lake Louis score.
Results Energy intake from the ad libitum meal was
reduced on MG2 compared to ZH (643 ± 308 vs.
952 ± 458 kcal, p = 0.001), but was similar to ZH on MG4
(890 ± 298 kcal). Energy intake on all test days was cor-
related with hunger/satiety scores prior to the meal and AMS
scores on MG2 but not with SpO2 on any of the 3 days.
Liking for high-fat foods before a meal predicted subsequent
energy intake on all days. None of the satiation hormones
showed significant differences between the 3 days.
Conclusion Reduced energy intake after rapid ascent to
high altitude is associated with AMS severity. This effect
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was not directly associated with hypoxia or changes in
gastrointestinal hormones. Other peripheral and central
factors appear to reduce food intake at high altitude.
Keywords Hypoxia  Dietary intake  Food preferences 
High altitude  Acute mountain sickness
Introduction
Millions of people travel to high or very high altitudes
([2,500 m above sea level) every year enjoying trekking,
climbing, skiing or for work, and this has stimulated
interest in high-altitude medicine dealing with the effects
of hypoxia on human physiology. Nutritional scientists
have observed a reduction in energy intake and weight loss
in healthy mountaineers in conditions of low oxygen
availability [14, 25, 29, 38]. Similar effects have been
documented in respiratory disease occurring at sea level.
Persistent hypoxia in this patient group is associated with
reduced energy intake, weight loss and poor disease out-
comes [7]. Moreover, the clinical relevance of hypoxia
independent of disease severity as a cause of these prob-
lems is supported by the finding that oxygen supplemen-
tation leads to weight gain in Chronic Obstructive
Pulmonary Disease [3].
The partial pressure of oxygen in inspired air falls from
about 150 mmHg at sea level to 84 mmHg at 4,559 m
(elevation of Capanna Margherita, the highest scientific
research station in Europe). At the same time, the incidence
of acute mountain sickness (AMS) increases from about
8 % below 4,000 m up to 40 % at 4,559 m [24]. Affected
patients complain of gastrointestinal symptoms such as
anorexia, nausea and vomiting as well as headache, malaise
and trouble sleeping [30]. Despite the association between
the two factors, the relative importance of hypoxia per se
and AMS as a cause of disturbed eating has not been
established. Further, the association between energy intake
and the severity of AMS is not consistent [25].
Several factors have been proposed to cause reduced
eating in hypoxia and AMS. Most refer to central neuro-
logical effects such as cerebral edema in AMS [37, 38];
peripheral and gastrointestinal factors, such as alteration in
the secretion of neuroendocrine gastrointestinal and pan-
creatic hormones [1, 11, 20, 32, 41], may however also be
important.
Additionally, alterations in food preferences may influ-
ence eating behavior at high altitude. Eating is generally
controlled by two complementary systems. Homeostatic
pathways increase the motivation to eat and restore energy
balance in case of depleted energy stores. Hedonic, reward-
based mechanisms, however, can override homeostatic
controls through cravings or increased desire to eat highly
palatable foods [19]. In animal studies, hypoxia decreased
the ‘incentive’ to consume food rather than changing
‘hunger’ or ‘appetite,’ thus shifting the taste spectrum
toward ‘unpalatable’ for a given diet [8].
The primary aim of this study was to assess changes in
food intake and preferences in healthy human subjects after
rapid ascent from 446 m to 4,559 m and to assess the roles
of hypoxia, AMS and satiation hormones in these changes.
Subjects and methods
Subjects
Thirty-two healthy, experienced mountaineers (20–
60 years old) were recruited by posting adverts in alpine
journals and by screening the ‘Contact list of rescued
people for high altitude disease’ of the last 5 years of the
Air Zermatt (Switzerland). This procedure ensured that the
study population was enriched by volunteers with experi-
ence of or susceptibility to AMS and high-altitude pul-
monary edema (HAPE) [22]. Sample size calculation for
the entire study was based on the pulmonary outcomes.
However, for this substudy, it was estimated that, with a
power of 90 % and an a-error of 0.05, a sample size of 21
subjects would be sufficient to detect the differences in
food intake between days (sample size calculation based on
[25, 38]). Exclusion criteria were more than three nights
above 2,500 m in the month preceding study entry; chronic
diseases necessitating regular medication such as arterial
hypertension, coronary heart disease and pulmonary
hypertension; patients with malignancy, transplant patients,
patients with clinically significant heart valve disease or
with congenital heart or lung disease; lactose intolerance,
celiac disease or relevant food allergies or specific food
requirements (e.g., vegetarians, Kosher) that could not be
provided in the mountain hut. The study was approved by
the Ethics Committee of the Canton of Zurich (EK-1677).
Written informed consent was received from all subjects.
Study design
This study represents the nutritional science arm of a larger
body of work. Other results (e.g., sleep studies, exercise
capacity, lung function, lipid metabolism and gastric
emptying) will be reported elsewhere. All examinations
were carried out at low (Zurich, 446 m above sea level,
ZH) and high altitude (Capanna Margherita, 4,559 m
above sea level, MG). For the low-altitude examinations,
subjects arrived in the late afternoon at the University
Hospital Zurich for the sleep studies with other examina-
tions carried out on the following day. For the high-altitude
examinations, participants ascended on day 0 by cable car
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from Alagna Valsesia (1,200 m, Italy) to about 2,980 m
and then hiked to the Rifugio Gniffeti at 3,650 m where
they spent one night. On day 1 (MG1), the participants
climbed to Capanna Margherita at 4,559 m. Nutritional
studies followed on day 2 (MG2) and day 4 (MG4).
All instruments used for the study were tested for
functionality at high altitude in a pressure chamber prior to
the ascent to Capanna Margherita.
Study protocol
The schedule of meals and other study procedures is pre-
sented in Fig. 1. On the morning of each test day, an
arterial and a venous catheter were placed in the forearm
for blood sampling. Thereafter, unsedated ultra-fine trans-
nasal esophagogastroduodenoscopy was performed to
examine the stomach and the duodenum (results to be
presented elsewhere). After a standardized breakfast lung
function tests, a maximal exercise capacity test on a cyclo-
ergometer and echocardiography at rest and during mod-
erate exercise were performed (to be presented elsewhere).
Nutritional examinations were all done in the afternoon
after the subjects had time to relax. Peripheral oxygen
saturation (SpO2) was monitored by pulse oximetry (finger
clip measurement using Infinity by Dra¨ger, Liebefeld,
Switzerland) and repetitive arterial blood gas analysis
(AVL 5 Radiometer, Copenhagen, Denmark).
Food intake
To control for differences in food intake before the low- and
high-altitude examinations, subjects were asked to fill in a
weighed food record for 4 days prior to the tests [12]. For
each subject, the amount of calories given for breakfast was
calculated to meet 30 % of their energy requirements based
on medium physical activity [16]. During the day, subjects
consumed a fixed energy meal of two muffins (total of
400 kcal; 35 % fat, 10 % protein, 54 % carbohydrates).
Four hours later, subjects completed a food preference
questionnaire and then consumed again two similar muffins
as a preload before an ad libitum dinner 90 min later. For
dinner, subjects were offered pasta, bolognese sauce, grated
parmesan cheese and two sorts of biscuits. They were free to
choose what and how much they ate; all food consumed was
weighed to the nearest gram on a kitchen scale by one of the
examiners. After dinner, subjects completed a food prefer-
ence questionnaire as before. After the preload, before and
after the dinner, hunger and satiety scores (hunger, desire to
eat, amount of food that could be eaten at the moment) as
well as gastrointestinal symptoms (feeling of stomach dis-
tension and nausea) were assessed on a 100-mm visual
analog scale anchored by the statements ‘not at all’ and
‘extremely.’ Unsweetened tea and water were available
ad libitum throughout all examination days.
Food preferences
To assess food preferences, a modified hedonic analysis
tool was used [9]. Twenty food stimuli were presented to
the subjects as color photographs. The food items were
assigned to four different categories: high-fat sweet, low-
fat sweet, high-fat savory and low-fat savory. Low-fat food
was characterized by less than 25 % and high-fat foods by
more than 50 % of the energy derived from fat. The dif-
ferent food stimuli used are listed in Table 1.
The assessment of liking (expected liking of each food
image category) and relative food preference (non-verbal,
motivated choice between food categories) was adapted
from Finlayson et al. [9]. For the ‘liking’ measurement, all
20 food items were rated on 100-mm visual analog scales
(‘How pleasant would you find the taste of this food at the
moment?’). For the assessment of ‘relative preference,’
forced choice methodology was used: Food items from
different categories were presented in pairs over a series of
Fig. 1 Schedule of meals and
blood sampling for each of the
study days (ZH, MG2, MG4)
Table 1 Food stimuli used in
the food preference
questionnaires
High-fat sweet Low-fat sweet High-fat savory Low-fat savory
Milk chocolate Jelly babies French fries Salt sticks
Brownies Fruit salad Chips Bread roll
Cranberry muffin Marshmallows Hard cheese Pasta with tomato sauce
Shortbread Meringues Salami Wild rice mix
Strawberry cream cake Dried fruits Salted peanuts Boiled potatoes
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trials and subjects had to choose ‘Which of those foods
would you prefer to eat at the moment?’ A total of 60
randomly selected combinations balanced within food
categories were used. Food preferences were assessed in a
hungry (4 h after fixed energy lunch) and in a satiated state
(after ad libitum dinner).
Blood sampling
A total of nine venous blood samples were taken in EDTA
tubes for the assessment of gastrointestinal hormones
starting with a fasting sample on waking and followed by
samples just before the consumption of the muffin lunch as
well as 30, 60, 90, 120, 180 and 240 min thereafter until
the ad libitum dinner. All blood samples were centrifuged
immediately, and the plasma was stored at -80 C (in
freezers at low altitude and in liquid nitrogen at high alti-
tude as well as during transport). Arterial blood for gas
analysis was taken during lung function test but not later
during the test meal. Before the ad libitum meal, the SpO2
was measured.
Acute mountain sickness
AMS scores were determined on each test day in the
Capanna Margherita based on the Lake Louise scoring
(LLS) system with five-rating questions with levels
between 0 and 3 (headache, gastrointestinal symptoms,
fatigue or weakness, dizziness/light-headedness and diffi-
culty sleeping), and the condition was diagnosed based on
the scores as well as repeated clinical examinations. A total
score [5 indicated AMS [23, 28].
Medication
Participants who developed severe AMS (Lake Louise
score [5) or had a history of high-altitude pulmonary
edema (HAPEs) were treated with 2 9 8 mg/day dexa-
methasone (9-Fluor-16a-methylprednisolone, dexametha-
sone 4 mg, Galepharm, Ku¨snacht, Switzerland) starting in
the evening of the first examination day (MG2; that is, after
the completion of all tests on MG2) until descent. Minor
symptoms like moderate headache and nausea were treated
with analgesics (Dafalgan, Paracetamol). Gastrointestinal
ulcer and reflux lesions were medicated with Nexium
(Esomeprazole). Diagnosis and prescription of medication
were conducted by medical doctors (MM, OG and HF).
Laboratory analysis
Analyses were carried out on plasma samples. Active
amylin and glucagon were measured using hormone kits
from Millipore Corporation (Milliplex MAP Human
Endocrine Assay, Millipore, Billerica, MA, USA); CCK-8
(active) and PYY 1-36 and PYY 3-36 (truncated form) were
measured using radioimmunoassay (RIA) Kits (Eurodiag-
nostica, Burgdorf, Switzerland) by Prof. Christoph Beg-
linger, University Hospital Basel; gastrin and EPO were
measured using immunoassays (Human Gastrin I (1–17),
Enzo Life Sciences, Lausen, Switzerland; Human Ery-
thorpoietin, Quantikine, R&D Systems, Abingdon, UK).
Data analysis
Data were analyzed using SPSS Statistics 17.0 (SPSS,
Chicago, IL, USA) and Graph Pad Prism Version 5.0 (San
Diego, CA, USA). The Kolmogorov–Smirnov test was
used to test the data for normal distribution. Where normal
distribution could not be assumed (nausea, feeling of dis-
tention), the nonparametric Wilcoxon test was used to test
for differences between the different days. For normally
distributed data, group comparisons were carried out using
t tests (unpaired or paired, as appropriate) and one-way
ANOVA. For the comparisons of hormone levels between
days and time points, two-way ANOVA with post hoc
Bonferroni correction was applied. Area under the curve
(AUC) was calculated for the hormones using Graph Pad
Prism with the concentrations ‘before muffin’ taken as
baseline. For food preference data, a general linear model
was used with a Bonferroni post hoc test. Multiple linear
regression models were carried out to analyze the impact of
food preferences on energy intake. Dietary intake data were
analyzed using the nutrition software EBISpro for Win-
dows 8.0 (J. Erhardt, University of Hohenheim, Germany)
including foods specific to Switzerland.
Results
Of the 32 subjects recruited, three withdrew informed
consent before the baseline examination, three withdrew it
after the baseline examinations in Zurich and one was
excluded due to illness at the baseline examination. Thus,
25 subjects [10 women, 15 men; age 43.8 ± 9.5 years
(range 22–60); BMI 23.8 ± 2.2 kg/m2 (range 20.2–31.4)]
completed the study under all conditions. One subject did
not finish meals and nutritional questionnaires during the
baseline examination, and two subjects were delayed in
their ascent the Capanna Margherita due to bad weather
and did therefore not participate in the nutritional surveys
on MG2 (excluded from analysis). Thus, data of 22 sub-
jects were available for nutritional analysis. Due to a food
shortage at the Capanna Margherita during a spell of bad
weather and thus no air transport, no cheese was available
for the ad libitum meal for seven participants; no macro-
nutrient analysis was conducted for this group.
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Hypoxia and AMS
As expected, ascent to 4,559 m caused significant hypox-
emia that was partially reversed by acclimatization and/or
the intake of dexamethasone at MG4 (Table 2). After the
consumption of the preload muffins on MG2, AMS was
found in nine participants (39 %). Although patients with
the most severe decrease in arterial oxygenation on MG2
tended to have more AMS symptoms and signs, there was
no significant correlation between LLS score and oxygen
pressure (PaO2) (r = 0.15, p = 0.494) and arterial oxygen
saturation (SaO2) (r = 0.12, p = 0.56).
Effects of dexamethasone on LLS, PaO2, PaCO2 as well
as O2 saturation are shown in Table 2. While LLS was
significantly different between treated and non-treated
groups on MG2, none of the other variables were. Fol-
lowing the treatment with dexamethasone, all nine partic-
ipants recovered from AMS on MG4. Among non-HAPEs,
one without AMS at MG2 developed the condition at MG4.
A mild HAPE without simultaneous AMS was diagnosed
in a HAPEs participant at MG3. This subject was treated
with tadalafil (20 mg/day) on MG4 until descent.
Food intake
Based on the analysis of the weighed food records, baseline
food intake did not differ at the time just before low- and
high-altitude examinations (data not shown).
Mean energy intake (±SD) from the ad libitum dinner
on the three examination days was ZH: 952 ± 458 kcal,
MG2: 643 ± 308 kcal and MG4: 890 ± 298 kcal. Energy
intake was lower on MG2 compared with ZH (p = 0.001),
but approached the baseline level on MG4 (p = 0.410
compared with ZH). The absolute amount of all
macronutrients eaten during the ad libitum dinner was
reduced on MG2 compared with baseline (p \ 0.05), but
the energy distribution from macronutrients did not change
(protein: ZH 19 %, MG2 = 19 %; carbohydrates:
ZH = 51 %, MG2 = 53 %; fat: ZH = 30 %,
MG2 = 29 %). However, on MG4, the proportion of total
energy intake from carbohydrates was reduced (48 %)
compared to both ZH and MG2, and that of fat was
increased (33 %; p \ 0.05). Mean energy intake (± SD) at
breakfast on all study days was 718 ± 95 kcal, and each
subject consumed two times two muffins, which amounted
to a total calorie intake of 800 kcal. Thus, the ad libitum
dinner contributed 39, 30 and 37 % of total energy intake
at ZH, MG2 and MG4, respectively.
Hunger/satiety scores
The hunger/satiety scores are shown in Table 3. The three
scores for ‘hunger,’ ‘desire to eat’ and ‘which amount of
food could you eat right now?’ given before the meal all
correlated positively with the actual energy intake during
the meal and on all 3 days (all p \ 0.01). While the hun-
ger/satiety ratings before the ad libitum meal were lower on
MG2 than in ZH and increased back to baseline on MG4,
the ratings given after the meal did not change significantly
between ZH and MG2, but were higher on MG4 compared
with MG2 (p \ 0.05). Total energy intake was negatively
correlated with AMS scores on MG2 (p = 0.043, r =
-0.468), but not on MG4, and it was not correlated with
sO2 on any of the study days. Similarly, in a stepwise
multiple regression, the only significant predictor for
energy intake on MG2 was AMS (LLS p = 0.042, b =
-0.471). BMI, age, gender and sO2 were not significant.
Effect of dexamethasone on energy intake
In total, 11 subjects were treated with dexamethasone on
the evening of MG2 (nine with AMS and two HAPEs
without AMS). Energy intake was lower at baseline in ZH
in those subjects who later received dexamethasone treat-
ment for AMS and/or HAPE susceptibility after study pro-
cedures on MG2 (treated 712 ± 382 kcal vs. untreated:
Table 2 Mean (±SD) Lake Louise Scores (LLS) as well as partial O2 (PaO2) and CO2 (PaCO2) pressure and arterial and peripheral O2
saturation (SaO2 and SpO2, respectively) grouped according to dexamethasone treatment/no treatment (n = 11 in each group)
ZH MG2 MG4
Non treated Treated Non treated Treated Non treated Treated
LLS score 0.9 ± 1.0 1.5 ± 1.2a 3.4 ± 1.4b 5.5 ± 2.3a,b 2.3 ± 1.3 1.7 ± 0.9c
PaO2 (kPa) 12.2 ± 1.1 11.9 ± 2.3 5.4 ± 0.6
b 5.0 ± 0.4b 5.8 ± 0.6b,c 5.9 ± 0.6b,c
PaCO2 (kPa) 5.2 ± 0.4 5.0 ± 0.4 3.8 ± 0.3
b 3.7 ± 0.3b 3.4 ± 0.4b,c 3.3 ± 0.3b,c
SaO2 (%) 95.6 ± 0.7 94.1 ± 5.3 77.9 ± 5.4
b 73.7 ± 6.8b 79.1 ± 5.1b 80.6 ± 6.0b,c
SpO2 (%) 97.4 ± 1.5 96.9 ± 1.3 78.4 ± 6.0
b 73.1 ± 9.5b 81.6 ± 8.6b 79.5 ± 7.7b
a Significantly different from non-treated group (independent samples t test, p \ 0.05)
b Significantly different from ZH
c Significantly different from MG2
Eur J Nutr (2013) 52:625–635 629
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1,192 ± 410 kcal; p = 0.010), but the pattern of change
over the days was similar in both groups (Fig. 2). Energy
intake was also lower on MG2 in the subjects that had to be
treated with dexamethasone (treated 501 ± 243 kcal vs.
untreated 802 ± 306 kcal; p = 0.029; note: treatment star-
ted only after the ad libitum dinner on that day), but it did not
differ between groups on MG4 (treated 817 ± 283 kcal vs.
untreated 964 ± 307 kcal; p = 0.255). Acclimatization and
dexamethasone treatment significantly contributed to
increase energy intake from MG2 to MG4 (p = 0.006 in the
non-treated, p = 0.015 in the treated subjects).
Food preferences
Liking
Liking scores of the different food categories (high fat, low
fat, sweet and savory) are presented in Table 4. Liking for
high-fat, low-fat and savory foods was significantly
increased on MG4 compared with MG2 (p \ 0.05); the
difference between MG4 and ZH was only significant for
savory foods (p \ 0.05). For sweet foods, no significant
differences were detected between days. A negative cor-
relation of liking scores for low-fat and savory foods on
MG2 (pre-meal) with AMS was present (p = 0.009, r =
-0.569 and p = 0.013, r = -0.546, respectively), while
none of the scores were related to AMS on MG4.
A stepwise multiple regression model was used to
investigate the effect of liking of the different food cate-
gories, and it revealed that for all days, liking for high-fat
foods was a predictor of total energy intake (ZH:
p \ 0.001, b = 0.763, R2 = 0.582; MG2: p = 0.008,
b = 0.588, R2 = 0.346 and MG4: p = 0.012, b = 0.527,
R2 = 0.277), while all other food categories and dexa-
methasone were not significant predictors.
Relative preference
The mean frequencies of food choices for the four cate-
gories are shown in Table 4. For all categories, frequencies
did not differ between the days, but they differed between
pre- and post-meal (p \ 0.01). For high-fat and sweet
foods, the frequency increased after food intake while it
decreased for low-fat and savory food on all days. Further,
a significant positive association between sweet frequency
(pre-meal) and AMS was seen on MG2 (p = 0.044,
r = 0.466).
To assess the relationship between measures of food
choice and energy intake, two independent composite
scores were created: relative taste preference: sweet fre-
quency—savory frequency; relative macronutrient prefer-
ence: high-fat frequency—low-fat frequency. Stepwise
multiple regression models revealed that relative prefer-
ence measures and dexamethasone treatment were not
predictors of energy intake on any of the days.
Gastrointestinal and pancreatic hormones
Blood samples were not available on all days from four of the
25 subjects. The plasma concentrations of glucagon, amylin,
peptide tyrosine–tyrosine (PYY) and cholecystokinin
Table 3 Hunger/satiety scores on a 100-mm visual analog scale directly before (pre-meal) and after (post-meal) the ad libitum meal (n = 22)
ZH MG2 MG4
Pre-meal Post-meal Pre-meal Post-meal Pre-meal Post-meal
Hunger (mm) 59 ± 8 34 ± 7 43 ± 8 31 ± 7 64 ± 6b 41 ± 7b
Desire to eat (mm) 58 ± 8 37 ± 7 40 ± 7a 30 ± 7 65 ± 6b 40 ± 7b
Amount of food (mm) 59 ± 7 42 ± 6 42 ± 6a 33 ± 6 61 ± 5b 42 ± 6b
ZH Zurich, low altitude, 446 m; MG2 Capanna Margherita day 2, first examination day at high altitude, 4,559 m; MG4 Capanna Margherita day
4, second examination at high altitude
a Significantly different compared to ZH (p \ 0.05)


























Fig. 2 Difference in energy intake at the ad libitum dinner between
subjects treated with dexamethasone on the evening of MG2 (n = 11)
and untreated subjects (n = 11). *Indicates significant differences
compared with the ‘dexamethasone yes’ group (p \ 0.05); indicates
significant difference compared to MG4; indicates significant
differences compared with ZH and MG4; the error bars are standard
error of the mean
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(CCK) on the different study days and time points are pre-
sented in Fig. 3. No significant changes in plasma glucagon
or gastrin concentrations were observed in response to food
intake or on the different days. Plasma amylin, PYY and
CCK increased postprandially but did not differ between
days.
Overall altitude increased amylin and PYY (p \ 0.05),
but there were no significant effects for individual
Table 4 Mean liking ratings on a 100-mm visual analog scale and mean frequency of food choice for different food categories in a fasted state
(before the preload) and after the ad libitum meal on all three examination days (n = 22)
ZH MG2 MG4
Pre-meal Post-meal Pre-meal Post-meal Pre-meal Post-meal
Liking score
High fat 42.0 ± 22.1 21.7 ± 14.8c 34.5 ± 17.0 21.6 ± 15.4c 46.1 ± 19.6b 27.6 ± 15.2c
Low fat 44.0 ± 15.5 22.8 ± 14.4c 42.6 ± 18.5 22.7 ± 15.1c 48.4 ± 12.3b 29.1 ± 15.3a,c
Sweet 32.7 ± 19.8 26.7 ± 16.2 25.8 ± 15.8 26.1 ± 21.8 29.4 ± 16.1 30.8 ± 19.4
Savory 53.3 ± 22.2 17.8 ± 17.1c 51.4 ± 24.1 18.3 ± 16.5c 63.1 ± 18.9a,b 25.9 ± 17.1a,c
Frequency of choice
High fat 28.4 ± 5.1 32.1 ± 4.1c 28.4 ± 5.8 30.1 ± 4.2a,c 28.4 ± 5.8b 30.3 ± 4.5a
Low fat 31.6 ± 5.1 27.9 ± 4.2c 32.9 ± 6.9 30.0 ± 4.1a,c 21.5 ± 5.7 29.7 ± 4.5a
Sweet 20.4 ± 6.2 36.9 ± 10.0c 19.3 ± 6.6 36.9 ± 11.1c 18.5 ± 6.8 34.1 ± 12.6c
Savory 39.5 ± 6.2 23.1 ± 10.0c 39.6 ± 8.3 23.1 ± 10.9c 41.3 ± 6.7 25.8 ± 12.5c
ZH Zurich, low altitude, 446 m; MG2 Capanna Margherita day 2, first examination day at high altitude, 4,559 m; MG4 Capanna Margherita day
4, second examination at high altitude
a Significantly different compared to ZH (p \ 0.05), paired samples t test
b Significantly different compared to MG2 (p \ 0.05), paired samples t test
c Significantly different compared to pre-meal on the same day (p \ 0.05), paired samples t test
Fig. 3 Plasma concentrations of glucagon, amylin, peptide tyrosine–
tyrosine (PYY) and cholecystokinin (CCK) over the entire study day
at the different examination days in healthy subjects (n = 19–21).
Zurich low altitude, 446 m; MG2 Capanna Margherita day 2, first
examination day at high altitude, 4,559 m; MG4 Capanna Margherita
day 4, second examination at high altitude; n = 21
Eur J Nutr (2013) 52:625–635 631
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differences between days at any time point. Except for
glucagon and CCK, the area under the curve (AUC)
throughout the postprandial period did not significantly
differ between days for any of the hormones.
Glucagon output was decreased postprandially (negative
AUCs) and the AUC for 240 min was significantly smaller
on MG4 compared with ZH (p = 0.023). Furthermore, in the
immediate (60 min) postprandial period, the AUC for glu-
cagon was smaller on MG2 compared with ZH (p = 0.043),
whereas the difference between MG4 and ZH was not sig-
nificant. The short-term response (30 and 60 min) of CCK
was greater on MG4 compared with ZH (p \ 0.05), but there
was no difference between ZH and MG2.
A non-significant trend was observed for amylin to be
increased on MG2 throughout the postprandial phase and
for PYY to be reduced on MG2 in the early postprandial
phase.
Discussion
This study presents a detailed assessment of dietary intake
and dietary preferences with measurements of gastroin-
testinal and pancreatic hormones in 22 healthy human
subjects on exposure to acute hypoxia following rapid
ascent from 446 m to 4,559 m. As expected, a marked
decrease in oxygen saturation indicative of severe hypoxia
was present after rapid ascent to high altitude with a fall in
sO2 from 97 % at low altitude to 76 % on the first day at
high altitude. At the same time, 39 % of the participants
experienced AMS symptoms that required treatment with
dexamethasone. The findings demonstrate that rapid ascent
to high altitude influences eating behavior in several dif-
ferent ways. Compared with the baseline examination in
Zurich (ZH), results for the first-day examination at high
altitude (MG2) showed (1) a significant reduction in energy
intake by 33 % in the ad libitum meal, (2) reduced hunger
and desire to eat scores and increased satiety ratings, which
correlated with the reduced energy intake, and (3) altered
food preferences where liking for all except sweet foods
was reduced.
Energy intake
The reduced energy intake at 4,559 m confirms the previ-
ous findings at similar altitudes where both men and
women were shown to reduce their energy intake by more
than 30 % after ascent to 4,300–5,100 m [15, 21, 33, 40].
The present study extends these findings by providing a
systematic analysis of certain factors that may contribute to
the energy intake reducing the effect of hypoxia following
rapid ascent to high altitude. These include the presence of
AMS symptoms and changes in baseline or postprandial
release of neuroendocrine gastrointestinal hormones that
influence energy intake and gastrointestinal function.
We demonstrated that energy intake on MG2 was
reduced and negatively correlated with AMS scores.
Interestingly, not only scores above the threshold for
diagnosis of AMS but even subclinical scores of AMS were
associated with energy intake; this can also be seen by the
fact that energy intake was reduced to a similar extent in
both the treated and the non-treated groups. Energy intake
returned to near normal levels on MG4, when also the
association with AMS scores was no longer present. Dif-
ferences between MG2 and MG4 cannot be attributed only
to acclimatization as 48 % of subjects were treated with
dexamethasone after study procedures ended on the even-
ing of MG2. Nevertheless, acclimatization or adaptation
appears to play an important role as the day-by-day
increase in energy intake was also observed in the non-
treated group. This is in agreement with the previous
studies which have shown that subjects can learn to eat
adequate amounts and that this can, during a longer
exposure, prevent or at least attenuate excessive weight
loss [4]. In contrast to AMS scores, there was no direct
association between hypoxemia and energy intake on any
study day. Thus, reduced energy intake after rapid ascent to
high altitude may not be determined by hypoxia per se, but
rather by the individual’s susceptibility to AMS. Only one
previous study reported on the association between AMS
and energy intake and found no significant correlation [25].
In this study, however, the sample size was very small (7
subjects), and they trekked to 4,700 m within 10 days as
compared to the 2 days in our study. The slower ascent
may have allowed for gradual acclimatization and thus a
different response to hypoxia.
Food preferences
We also studied changes in food preferences that may be
associated with reduced eating in hypoxic conditions at
high altitude, an assessment that, to our best knowledge,
was never done in this form before. Liking ratings for high-
fat foods assessed before the meal were good predictors for
energy intake, independent of day and altitude; however,
neither changes in liking nor changes in relative food
preference ratings were predictors for changes in total
energy intake from baseline to high altitude. Thus, overall,
food preference is not the major cause of reduced energy
intake at high altitude although it may have some impact.
There were however significant effects on specific food
items. Palatability (liking) of all food items except for
sweet food was reduced after a meal at baseline and at high
altitude. This confirms that the strong hedonic response
induced by sweet foods may override homeostatic signals
of satiety [9]. More interestingly, and in contrast to the
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previous studies [27, 31], we also noted a significant
increase in the palatability of savory foods at high altitude
and an interaction between food preferences and suscepti-
bility to AMS. This increase may be related to sodium
depletion after 3 days exertion at high altitude. Sodium
depletion in humans and rats leads to an increased palat-
ability of salt [2, 34], and it is known that ascent to high
altitudes leads to sodium diuresis linked to a suppression of
the renin-angiotensin-aldosterone system [42]. This effect
was weaker in patients with AMS. Indeed, there was a
positive correlation between the frequency for sweet foods
and a negative correlation for savory foods with AMS
scores on MG2. Thus, in contrast to subjects that remain
well at altitude, subjects that develop AMS seem to prefer
sweet foods over savory foods. These effects may be
mediated through homeostatic mechanisms involving
renin-angiotensin-aldosterone system that control sodium
balance. Such mechanisms also have been linked to per-
formance at altitude and survival on intensive care [26]. In
consequence, during expeditions to high altitude, individ-
ual food choices may reflect underlying physiologic
adaptation to hypoxia and may, potentially, influence the
likelihood of developing AMS.
Gastrointestinal neuroendocrine hormones
The release of anorexigenic neuroendocrine hormones such
as glucagon, amylin CCK and PYY from the gastrointes-
tinal tract after a meal is considered to play a key role in
meal-ending satiation [10], but their role in reduced eating
at high altitude is less clear. Results for glucagon are
contradictory; whereas an animal study in rats demon-
strated increased glucagon secretion under hypoxic condi-
tions (simulated altitude of 5,000 m) [6], a human study
found decreased concentrations at high altitudes (7,134 m)
[5]. In our study, there was no change in glucagon plasma
levels between baseline and high altitude on MG2 or on
MG4. We also observed no significant increase in the
postprandial glucagon concentration and no differences
between test days. These negative results may be due to the
relatively low protein content of the muffin lunch
(400 kcal, 9.9 g protein), which may be below the level
required to stimulate a substantial glucagon release [17].
Indeed, against our expectations, postprandial AUC for
glucagon were even negative, indicating a decrease in
glucagon secretion after food intake on all examination
days. This argues against a major role of glucagon in
reduced eating during the ad libitum dinner on MG2,
although the limitations noted above apply.
The anorexigenic hormone CCK has been shown to be
increased in human subjects on the second day after ascent to
5,100 m [1]; this increase has been linked to the hypoxia-
inducible factor (HIF) [1, 13]. In contrast to these findings,
we did not see significant differences in plasma CCK con-
centrations between samples taken at baseline in Zurich and
on any of the 2 days at high altitude. Of note, even though the
altitude was similar in both studies, the duration of ascent
varied considerably. While our subjects ascended to 4,559 m
in only 2 days, the subjects in the other study climbed to
5,100 m in 20 days, providing much more time for accli-
matization not only to hypoxia but also to exertion. Inter-
estingly, the AUCs for CCK, indicative of total CCK output,
were significantly higher on MG4 in the early postprandial
phase (0–30 or 0–60 min), whereas there was no change on
MG2. Because eating was significantly reduced on MG2,
where no change in CCK was observed, but not on MG4, it
seems unlikely that altered CCK secretion contributed to the
changes in food intake in this setting.
The contribution of PYY, amylin or gastrin to reduced
eating in hypoxic conditions has not been studied previ-
ously. Similar to glucagon and CCK, all three hormones
are implicated in the control of energy intake; however, no
significant differences in any of these hormones were
observed between the three examination days. Further,
there were no significant differences in the AUCs between
test days for amylin and PYY, neither over the entire
postprandial period nor for shorter time intervals.
Overall, it therefore appears unlikely that changes in the
secretion of the neuroendocrine hormones studied here are
involved in the reduced dietary intake documented after
rapid ascent to 4,559 m.
Limitations of this study include difficulty differentiating
the effect of hypoxia on eating behavior from the effect of
exertion. Subject activity on ZH, MG2 and MG4 test days
was tightly controlled, but there was no equivalent prior to
the ZH test day to the rapid ascent to high altitude on MG1.
Nevertheless, even though a short-term reduction in hunger
and energy intake has been observed directly following
intense exercise [39], the normal longer-term response to
physical activity is to increase energy intake [36], and the
opposite was observed on MG2. Thus, if anything, the
results may underestimate the effects of hypoxia on appetite
and energy intake. Similar to most nutritional studies,
forced eating patterns were applied, and the size of muffin
test meals was not adapted to the energy requirements of the
subjects. Furthermore, the muffin meal may not have been
adequate to provoke normal postprandial changes in gas-
trointestinal hormones, and the sample size may have been
too small, as certain non-significant trends were observed.
Finally, the use of dexamethasone in some study partici-
pants certainly affected the results on MG4. Due to ethical
concerns, it was not possible to randomize the subjects into
treated and non-treated groups during a 5-day stay at
4,559 m; all subjects showing severe AMS symptoms on
the evening of MG2 were treated. It is important to mention,
however, that only one participant required steroid
Eur J Nutr (2013) 52:625–635 633
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treatment prior to the measurements on MG2 and that the
analysis found similar trends in each subgroup.
In conclusion, our data suggest that reduced food intake
after rapid ascent to high altitudes was mediated by a
variety of factors, which are still not completely under-
stood. Reduced energy intake under hypoxic conditions at
altitude was independently related to both reduced appetite
before the meal and the presence of AMS symptoms.
Altered food preferences were also present, although they
were probably not the main drive. Changes in energy
intake and food preferences were not related to altered
secretion of gastrointestinal hormones under the current
experimental conditions and, thus, the underlying mecha-
nism by which hypoxia exerts its effects on appetite, and
eating behavior remains uncertain. One possible mecha-
nism that was not explored here would be a reduction in
appetite mediated by elevated serum leptin concentrations
that have been found previously at high altitudes [35].
Furthermore, plasma sodium was found to be reduced in
subjects suffering from AMS at high altitude as a result of
reduced urine flow and thus a dilution through total body
water [18]. However, whether this would directly affect
food intake or appetite or whether changes in sodium
intake might affect severity of AMS was not studied.
Treatment with dexamethasone was an effective
approach for reversing AMS symptoms and improving
energy intake. Whether the prophylactic administration of
steroids prior to ascent might help to prevent the early
decrease in food intake, remains to be determined.
These findings may also be relevant to understand the
effects of hypoxia in other conditions. Using the model of
high-altitude studies for achieving a better understanding
of the effect of hedonic and homeostatic systems in the
control of appetite and energy intake in a hypoxic state
might also help in the nutritional management of patients
suffering from respiratory diseases, although it remains to
be determined whether the mechanisms are truly
comparable.
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